The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
The OTEZLA® international website
This site is intended for healthcare professionals outside the U.S.
aESTEEM 1 study. Data as observed; includes patients initially randomized to OTEZLA 30 mg BID or placebo at week 0 who were PASI-75 responders at week 32 and continued to receive OTEZLA through week 52.
Baseline
Week 16
Individual results may vary.
Week 32
Individual results may vary.
*In patients with nail psoriasis at baseline (NAPSI score >1; 558/844, 66.1%).
†Full analysis set, LOCF.
‡Actual real-world OTEZLA patient. Property of Amgen Inc.
On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
